ot applicable
- Conditions
- cancer-related painMedDRA version: 17.0Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
- Registration Number
- EUCTR2013-001877-26-HR
- Lead Sponsor
- Grünenthal GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 220
Informed consent signed indicating that the subject understands the purpose of and procedures required for the trial and is willing to participate in the trial.
Subjects must be at least 18 years of age at the Enrollment Visit (Visit 1).
Women of childbearing potential must have a negative pregnancy test at Visit 1 and must not be lactating at Visit 1.
Subjects must be willing to use medically acceptable and highly effective methods of birth control.
Subjects who have completed treatment in KF6005/07 and are still in need of around-the-clock pain analgesia with strong opioids.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 128
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 92
The subject has a clinically significant disease or condition other than cancer which in the investigator's opinion may affect efficacy or safety assessments.
Known to or suspected of not being able to comply with the protocol and the use of cebranopadol.
Subjects taking forbidden concomitant medications or not being able to follow the rules of use of concomitant treatment.
History of torsade de pointes and/or presence of risk factors for torsade de pointes (e.g., The subject has a clinically significant disease or condition other than cancer which in the investigator's opinion may affect efficacy or safety assessments.
Known to or suspected of not being able to comply with the protocol and the use of cebranopadol.
Subjects taking forbidden concomitant medications or not being able to follow the rules of use of concomitant treatment.
History of torsade de pointes and/or presence of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, bradycardia).
Concurrent participation in another trial (except participation in KF6005/07) or planning to be enrolled in another clinical trial (i.e., administration of experimental treatment in another clinical trial) during the course of this trial, or previous participation in this trial.
Employees of the sponsor, investigator, or trial site or family members of the employees, sponsor, or investigator.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The primary objective of this trial is to describe the safety and tolerability of prolonged exposure to cebranopadol in subjects suffering from cancer related pain;Secondary Objective: Not applicable;Primary end point(s): The primary endpoint for this trial is the incidence of treatment emergent adverse events (TEAEs).;Timepoint(s) of evaluation of this end point: First intake of IMP up to the time of the last protocol scheduled contact
- Secondary Outcome Measures
Name Time Method Secondary end point(s): The secondary safety endpoint for this trial is the intensity of TEAEs. The secondary efficacy endpoint for this trial is the average pain intensity (11-point numerical rating scale [NRS]) in the last week during the Treatment Period and changes from baseline (Visit 1).;Timepoint(s) of evaluation of this end point: Secondary safety endpoint: first intake of IMP up to the time of the last protocol scheduled contact. Secondary efficacy endpoint: last week during the Treatment Period and changes from baseline